90Y-Ibritumomab tiuxetan

90Y-Ibritumomab Tiuxetan (Zevalin®)

March 23, 2024March 23, 2024
Beta (β-) emitters, Therapeutics

90Y-Ibritumomab Tiuxetan (Zevalin®) is a radiopharmaceutical used in the treatment of certain types of non-Hodgkin’s lymphoma. It consists of two main components: the monoclonal antibody… Read More »90Y-Ibritumomab Tiuxetan (Zevalin®)